Related Experiment Video

Updated: Jun 23, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease

Elahe A Mostaghel1, Bruce Montgomery, Peter S Nelson

  • 1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Urologic Oncology
|May 6, 2009
PubMed

Insights

Residual androgens from adrenal or prostate sources fuel castration-resistant prostate cancer. Targeting androgen biosynthesis pathways offers a promising strategy for improved treatment outcomes.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Prostate cancer treatment often involves androgen deprivation therapy (ADT) to reduce testosterone levels.
  • Recurrent, castration-resistant prostate cancer (CRPC) can progress despite ADT, suggesting alternative androgen sources.
  • Residual androgens, potentially from adrenal or prostate origins, are implicated in CRPC development.

Purpose of the Study:

  • To reassess the concept of total androgen deprivation in prostate cancer treatment.
  • To investigate the role of residual androgens in the progression to castration-resistant disease.
  • To explore novel therapeutic strategies targeting androgen biosynthesis.

Main Methods:

  • Review of emerging evidence on androgen sources in CRPC.
  • Analysis of adaptive responses in prostate cancer cells to castration.
  • Evaluation of targeting androgen biosynthesis enzymes.

Main Results:

  • Testicular androgen ablation does not eliminate all androgen sources.
  • Prostate cancers adapt to low-androgen environments by up-regulating androgen biosynthesis enzymes.
  • Androgen receptor (AR) pathway inhibition efficacy requires tissue-level assessment, not just serum levels.

Conclusions:

  • Total androgen deprivation may be insufficient for optimal prostate cancer treatment.
  • Targeting adrenal and intracrine androgen sources is crucial for managing CRPC.
  • Inhibiting androgen biosynthesis enzymes presents a potential therapeutic avenue for localized and metastatic prostate cancer.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...